Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...

We are at a critical crossroads for the clinical use of ctDNA in early-stage breast cancer, according to Dr. Heather A. Parsons. “What if we could reliably identify molecular re ...

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

While Enhertu (trastuzumab deruxtecan, T-DXd) is an established treatment for patients with HER2-low metastatic breast cancer (mBC), there has been limited information about how well it works for ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

Fewer older women with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer are undergoing routine sentinel lymph node biopsy (SLNB), according to data that were presented at the ...

Resilience plays a key role in helping patients adjust after cancer treatment ends, according to Frank Penedo, professor of ...

Real-world data show that Enhertu (fam-trastuzumab deruxtecan-nxki) was tolerated as well in the community setting, where patients had higher disease burden, as in the clinical trial setting, ...

A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.

Long-term results from a phase 2 study presented at the 27th European Congress on Gynaecological Oncology (ESGO 2026) in Hong ...

Inflammation has been linked to symptoms that many survivors experience, including fatigue, pain, cognitive difficulties and mood changes. The idea behind this research is that if we can reduce ...